{"entity":{"id":"nct01876043","kind":"trial","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","aka":[],"tldr":"A phase 2 trial of Plitidepsin in Liposarcoma, run by Institut Bergonié, recorded as terminated on the registry.","summary":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial is a phase 2 interventional study registered as NCT01876043 by Institut Bergonié, with 24 participants recorded, started 2012-02 and due to reach its primary completion in 2015-04. Interventions recorded: plitidepsin. Conditions recorded: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma.\n\nLinked to the drug Plitidepsin because the registry names it among its interventions and Liposarcoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01876043","url":"https://clinicaltrials.gov/study/NCT01876043"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["liposarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["plitidepsin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01876043","phase":"2","setting":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","sponsor":"Institut Bergonié","started":"2012-02","yearReported":2019,"enrolled":24,"enrolledBasis":"registry","outcomes":[{"endpoint":"1-year Overall Survival (OS) Rate","unit":"%","arms":[{"name":"Plitidepsin","n":22,"value":40.9,"note":"95% CI 20.9 to 60.1; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01876043?tab=results"},{"endpoint":"Progression-free Survival","unit":"months","arms":[{"name":"Plitidepsin","n":22,"value":1.6,"note":"95% CI 1.4 to 2.6; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01876043?tab=results"}]},"route":"/trials/nct01876043/","neighbours":{"cancer":[{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/"}],"drug":[{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/"}]}}